Summary of Mindray Medical Conference Call Company Overview - **Company**: Mindray Medical - **Fiscal Year**: 2024 - **Key Financials**: - Net profit attributable to shareholders increased by 4.36% year-on-year - Operating cash flow net amount increased by 12.38% to 12.432 billion CNY - Total revenue for 2024 was 36.726 billion CNY, a 5.14% increase from the previous year - Planned cash dividends for 2024 totaled 7.602 billion CNY, with a payout ratio of 65.15% [2][3][4] Industry Performance - **International Market**: - Strong performance with a growth of 21.28%, accounting for 45% of total revenue - Asia-Pacific region grew nearly 40%, while Europe rebounded with over 30% growth - High-potential businesses such as minimally invasive surgery, animal healthcare, and cardiovascular accounted for nearly 10% of international revenue [2][5] - **Domestic Market**: - Domestic revenue decreased by 5.1% due to weak tendering and the impact of DRG 2.0 - Anticipated recovery in growth by Q3 2025 as local fiscal pressures ease and medical equipment update projects commence [2][5] Product Line Performance - **In Vitro Diagnostics (IVD)**: - Grew by 10.82% overall, with international growth exceeding 30% - Domestic market affected by policy changes but market share increased [2][6][7] - **Medical Imaging**: - Grew by 6.60%, with international growth over 15% - Launch of high-end ultrasound Verona A20 contributed significantly [2][7] - **Life Information and Support**: - Declined by 11%, but international markets saw double-digit growth - Domestic market maintained leading market share in monitoring and respiratory products [2][7] Research and Development - **R&D Investment**: - 2024 R&D investment was 4.008 billion CNY, accounting for 10.91% of revenue - Continued focus on innovation with multiple new product launches in various fields [3][11][12] Sustainability and ESG - **Sustainability Initiatives**: - Maintained MSCI ESG rating of A - Set carbon reduction goals with a reported 11.6% decrease in carbon intensity by the end of 2024 compared to 2021 [2][13] Market Outlook - **Domestic Market Potential**: - Confidence in long-term growth despite recent slowdowns - Anticipated acceleration in medical equipment updates and government investments in healthcare [10][14] - **International Market Strategy**: - Plans to enhance supply chain and marketing strategies to mitigate tariff impacts - Targeting a long-term goal of 30% domestic and 70% international revenue [15][17] Challenges and Risks - **Tariff Impacts**: - U.S. tariffs have not significantly affected North American business, with a compound annual growth rate of 10% from 2018 to 2023 - Ongoing adjustments to supply chain and material sourcing to manage costs [18][19] Future Growth Strategies - **Five-Year Plan**: - Focus on digitalization, streamlined production, and international expansion - Emphasis on integrating AI and IT with medical devices to enhance clinical decision-making [20][21] - **IVD Growth**: - Expected to remain a key growth driver with new product launches and competitive upgrades planned [23][24] Conclusion - **Overall Outlook**: - Mindray Medical is positioned for continued growth through strategic investments in R&D, international market expansion, and a focus on sustainability, despite facing challenges in the domestic market and external economic pressures [30][31]

Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of RMB 328.30 [7][8]. Core Views - The company reported a revenue of RMB 367.26 billion and a net profit attributable to the parent company of RMB 116.68 billion for 2024, reflecting a year-on-year growth of 5.1% and 0.7% respectively. The profit was below market expectations due to delays in domestic equipment upgrade policies [1]. - The company is expected to achieve steady growth in 2025, driven by the acceleration of domestic equipment upgrade policies and ongoing efforts in product promotion both domestically and internationally [1]. - The company’s three core business segments are projected to perform well in 2025: 1. IVD segment revenue reached RMB 137.65 billion in 2024, with a year-on-year increase of 10.8% and strong overseas growth [2]. 2. Medical imaging segment revenue was RMB 74.98 billion, up 6.6% year-on-year, supported by the launch of high-end products [2]. 3. Life information and support segment revenue was RMB 135.57 billion, down 11.1% year-on-year, but expected to rebound in 2025 due to improving domestic policies [2]. Summary by Sections Financial Performance - The company’s revenue for 1Q25 was RMB 82.37 billion, with a net profit of RMB 26.29 billion, showing a year-on-year decline of 12.1% and 16.8% respectively, but a quarter-on-quarter increase of 13.8% and 154.9% [1]. - The company’s revenue forecast for 2025 is RMB 40.545 billion, with a projected net profit of RMB 12.84 billion, reflecting a growth of 10.04% [6]. Market Expansion - The company’s overseas revenue reached RMB 164.34 billion in 2024, growing by 21.3%, with significant contributions from the Asia-Pacific and European regions [3]. - Domestic revenue was RMB 202.92 billion, down 5.1% year-on-year, but expected to improve in 2025 due to the release of medical infrastructure orders and enhanced competitiveness [3]. Profitability and Valuation - The EPS forecast for 2025 is adjusted to RMB 10.59, with a PE ratio of 31x for 2025, leading to a target price of RMB 328.30 [4]. - The company is recognized as a leading domestic medical device manufacturer with strong brand influence and a continuously improving global sales network [4].

Key Insights - The report highlights the growth in the active bond fund sector, with a total of 3,263 funds and a total scale of 7.90 trillion yuan, reflecting a 1.0% increase quarter-on-quarter [7][8] - The performance of active bond funds showed mixed results, with short-term pure bond funds performing well due to rising government bond yields, while mixed secondary bond funds saw increased volatility [7][8] - The report indicates a shift in asset allocation within bond funds, with a decrease in bond positions and an increase in equity positions, particularly in sectors like non-ferrous metals and pharmaceuticals [8] Group 1: Active Bond Fund Overview - As of the end of Q1 2025, the number of active bond funds increased by 0.8% compared to the previous quarter, while the total fund scale rose by 1.0% [7] - In Q1 2025, 43 new active bond funds were issued, totaling 783.7 billion yuan, which is a 16.7% decrease from the previous quarter [7] - The issuance of medium to long-term pure bond funds decreased by 31.5%, while mixed secondary bond funds saw a 65.1% increase in issuance [7] Group 2: Company-Specific Insights - For Mindray Medical (300760.SZ), the company reported a revenue of 36.726 billion yuan in 2024, a year-on-year increase of 5.14%, with a net profit of 11.668 billion yuan, up 0.74% [9][10] - The company’s international business grew by 21.28%, accounting for approximately 45% of total revenue, indicating a strong international expansion strategy [11] - The report anticipates a recovery in domestic business by Q3 2025, despite a significant year-on-year decline in Q1 2025 [11] Group 3: Industry Trends - The report on Haibo Technology (688411.SH) indicates a revenue of 8.270 billion yuan in 2024, a growth of 18.44%, with a focus on energy storage systems [14][15] - The company’s energy storage product output and sales saw significant increases, with a 35.40% rise in production and a 90.19% increase in sales [15] - The report emphasizes the company’s leading position in the domestic energy storage market and its successful international partnerships [17] Group 4: Financial Performance - For Sanmei Co., Ltd. (603379.SH), the company achieved a revenue of 4.040 billion yuan in 2024, a 21.17% increase, with a net profit growth of 178.40% [24][25] - The report highlights the impact of rising refrigerant prices and strong demand from the home appliance and automotive sectors on the company’s financial performance [25][26] - The company is expected to maintain strong performance due to favorable supply-demand dynamics in the refrigerant market [28] Group 5: Future Outlook - The report suggests that the domestic medical device market, particularly for Mindray Medical, is poised for recovery, with expectations of improved performance in 2025 [11][12] - Haibo Technology is projected to continue its growth trajectory, supported by its strong market position and international expansion efforts [17][18] - Sanmei Co., Ltd. is expected to benefit from ongoing demand in the refrigerant market, with projections for significant profit growth in the coming years [28]

Core Viewpoint - In 2024, the pharmaceutical industry faces pressure due to multiple national policies, leading to a structural differentiation where top companies perform well while mid-tier and lower companies struggle [1] Group 1: Industry Performance - As of the report, 483 out of 499 listed pharmaceutical companies have released their 2024 performance, achieving a total revenue of 2.49 trillion yuan, flat year-on-year, with a net profit of 139.72 billion yuan, down 12% [1] - Among these companies, 229 reported revenue growth while 254 experienced declines [1] - The leading company, Shanghai Pharmaceuticals, reported revenue of 275.25 billion yuan, a 5.75% increase, and a net profit of 4.55 billion yuan, up 20.82% [1] Group 2: Profitability Insights - Of the 483 companies, 363 reported positive profits while 120 incurred losses; 224 companies saw year-on-year growth in net profit [2] - Mindray Medical emerged as the "profit king" with 36.73 billion yuan in revenue and a net profit of 11.67 billion yuan [2] - North China Pharmaceutical achieved the highest net profit growth at 2496.8%, reaching 127 million yuan, attributed to product structure adjustments and cost management [2] Group 3: Mid-Tier Company Challenges - Mid-tier companies are facing growth bottlenecks due to high base effects from 2023, inclusion in centralized procurement, and price reductions in medical insurance [3] - Traditional Chinese medicine companies have seen net profit declines exceeding 50% due to losing bids in core product procurement [3] - However, as centralized procurement stabilizes, some companies like Dabo Medical and Weigao Orthopedics are expected to see significant improvements in 2024 [3] Group 4: International Expansion - Amid intensified domestic competition, pharmaceutical companies are accelerating their international expansion [4] - United Imaging achieved overseas revenue of 2.27 billion yuan, a 35.07% increase, accounting for 22% of total revenue [4] - Watson Bio reported overseas revenue of 570 million yuan, a growth of approximately 98%, with a three-year compound growth rate of 105% in overseas business [4]

作者 | 大健康萌主 数据支持 | 勾股大数 据（www.gogudata.com） 2025 年，全球医疗健康产业迎来时代大考。关税壁垒重构叠加地缘政治波动，一系列悬而未决的政策，进一步增加了行业的不确定性。 当不确定性成为新常态，成立 34 年的迈瑞医疗却交出了穿越周期的答卷： 自 2018 年上市以来，公司实现营收与归母净利润连续七年双增长， 2024 年的营收为 2019 年的 2.2 倍，归母净利润为 2019 年的 2.5 倍。 业绩的翻倍增长，无异于用 5 年时光"再造了一个迈瑞"，这在国内外宏观环境剧烈变化的挑战下尤其难得。 更难能可贵的是，在保持高强度研发投入（ 2024 年研发支出占比 10.91% ）的同时，公司持续践行高比例分红承诺，最新年度现金分红金 额蝉联行业榜首。当众多企业选择储粮过冬时，这种 " 既造血又输血 " 的双轨能力，恰恰折射出企业对未来发展空间的预判。 在产业变革与市场波动双重压力下，支撑迈瑞医疗从容前行的核心竞争力究竟是什么？ 连续七年高比例分红 01 年派现规模突破76亿元 从最新披露的分红方案可以看出，迈瑞底气十足。 根据 2024 年度分红预案显示，公司拟向全 ...

想不到一向"浓眉大眼"的迈瑞，也"暴雷"了。 4月28日晚间，在迈瑞医疗公布年报和一季报后，股吧和雪球的讨论区便瞬间炸开了锅。 迈瑞医疗2024年营业收入367.3亿元，同比增长5.1%；归母净利润116.7亿元，同比增长0.7%，剔除 财务费用影响后的增速为4.4%；经营性现金流净额124.3亿元，同比增长12.4%。 2025年第一季度，公司实现收入 82.37 亿元，同比-12.12%；实现归母净利润 26.29 亿元，同 比-16.81%。 对于常年保持20%增长的"好学生"迈瑞来说，这张连续两个季度业绩miss的成绩单，还是有些过于"惊 喜"了。 但出乎大家意料的是，4月29日开盘之后，迈瑞医疗在小幅低开以后迅速冲高，收盘微涨。考虑到最近 A股对于业绩不达预期这事比较敏感，更显得难能可贵。 由此可见在一季报中"前低后高，逐季改善"的业绩指引，还是赢得了机构投资者的信任票。 而除了实实在在的业绩数字之外，迈瑞医疗的数智化转型，在更高的维度上决定了企业的未来。 从"数据孤岛"到"智能生态" 从ChatGPT到DeepSeek，从IBM Watson到AlphaFold3。没有人可以否认，全球医疗行业正在 ...

Core Viewpoint - The impact of the U.S. tariff policy on Chinese pharmaceutical companies is relatively limited, with many companies reporting normal operations and minimal effects from the tariffs [1][2][3][4][5]. Company Responses - Heng Rui Pharmaceutical stated that overseas sales account for only 2.56% of its revenue, indicating that U.S. tariffs will have a minimal impact on its business [1]. - Han Yu Pharmaceutical emphasized its diversified market layout, which mitigates risks from single market policy changes, and reported no significant impact from the tariffs [2]. - WuXi AppTec acknowledged that tariffs would have some effect but deemed it manageable, highlighting their optimized supply chain and global presence [3]. - Kang Tai Biological reported no exports to the U.S. and is focusing on markets along the Belt and Road, indicating a strategic shift to other regions [4]. - Mindray Medical confirmed that while some raw materials are imported from the U.S., they are taking measures to ensure supply safety and view the tariff impact as a one-time issue [4]. Industry Trends - The Chinese vaccine industry is rapidly developing, with companies like CanSino Biologics transitioning from followers to leaders in vaccine technology, focusing on domestic innovation [6][7]. - The overall sentiment among companies is that the tariff policy presents an opportunity for domestic product substitution, with many firms prepared to adapt to changing market conditions [5][8]. - Companies are increasingly focusing on technological innovation and expanding into emerging markets to counteract potential supply chain disruptions caused by tariffs [5][6][7].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing short-term pressure but is expected to improve gradually quarter by quarter [1] - In 2024, the company achieved total revenue of 36.726 billion yuan, a year-on-year increase of 5.14%, and a net profit attributable to shareholders of 11.668 billion yuan, a year-on-year increase of 0.74% [7] - The company anticipates a turning point in 2025, despite short-term challenges in the domestic market [7] Financial Performance Summary - Total revenue projections for the company are as follows: 39.369 billion yuan in 2025, 45.061 billion yuan in 2026, and 52.403 billion yuan in 2027, with respective year-on-year growth rates of 7.20%, 14.46%, and 16.29% [1] - Net profit attributable to shareholders is projected to be 11.960 billion yuan in 2025, 13.131 billion yuan in 2026, and 15.280 billion yuan in 2027, with year-on-year growth rates of 2.50%, 9.79%, and 16.37% [1] - The latest diluted EPS is expected to be 9.86 yuan in 2025, 10.83 yuan in 2026, and 12.60 yuan in 2027 [1] Business Segment Performance - The Life Information and Support business generated revenue of 13.557 billion yuan in 2024, a decrease of 11.11% year-on-year, while the International Life Information and Support business saw double-digit growth [7] - The In Vitro Diagnostics (IVD) business achieved revenue of 13.765 billion yuan, a year-on-year increase of 10.82%, marking its first time exceeding the Life Information and Support business in revenue [7] - The Medical Imaging segment generated revenue of 7.498 billion yuan, with international business growth exceeding 15% [7] - The Electrophysiology and Vascular Intervention segment generated revenue of 1.439 billion yuan, with the acquisition of control over Huitai Medical to enhance cardiovascular segment capabilities [7] Innovation and Growth Drivers - The company launched several innovative products in 2024, including advanced medical systems and AI-driven solutions to improve patient care and operational efficiency [7] - The company maintains a strong competitive position due to its diverse product lines and continuous innovation [7]

Core Viewpoint - Mindray Medical (300760.SZ) reported a revenue of 36.726 billion RMB for 2024, marking a year-on-year growth of 5.14%, and a net profit attributable to shareholders of 11.668 billion RMB, with a growth of 0.74% year-on-year, maintaining seven consecutive years of revenue and net profit growth since its A-share listing in 2018 [1][2] Financial Performance - The company plans to distribute a cash dividend of 5.60 RMB per 10 shares, totaling 679 million RMB for 2024, leading to a cumulative cash dividend of 7.602 billion RMB for the year, with a cash dividend ratio of 65.15% [1][2] - Since its listing, Mindray has distributed over 34 billion RMB in dividends and has not engaged in refinancing, with a cash dividend ratio of 60.72% for 2023 [2] - The company has outlined a shareholder return plan for the next three years (2025-2027), committing to at least one profit distribution annually, with cash distributions not less than 65% of the distributable profits [2] Business Segments Performance - The Life Information and Support segment generated 13.557 billion RMB in revenue, with the minimally invasive surgery business growing over 30% year-on-year [3] - The In Vitro Diagnostics segment achieved 13.765 billion RMB in revenue, a year-on-year increase of 10.82%, becoming the largest business segment [3] - The Medical Imaging segment reported 7.498 billion RMB in revenue, with a growth of 6.6% year-on-year, and the high-end ultrasound system Resona A20 generated over 400 million RMB in its first year [3] R&D and Innovation - Mindray's R&D investment reached 4.008 billion RMB in 2024, accounting for 10.91% of total revenue, with a total of 11,773 patent applications filed [3] Market Environment and Growth Prospects - The domestic procurement environment is recovering, and the company anticipates significant growth in international markets, with a 21.28% increase in international business revenue, now accounting for approximately 45% of total revenue [5][6] - The company is adapting to challenges such as tariffs and is confident in maintaining supply chain stability while aiming to enter the top 20 global medical device companies [7]

正式报名：首届全球心血管大会 | 赠送纸质白皮书 合作伙伴征集：2025全球手术机器人大会 2025年4月28日，迈瑞医疗发布2024年年报以及2025年第一季度季报。2024年年度营业收入达到 367.3亿元 ，2025年第一季度营业收入达到 82.4亿 元。 公司预计2025年上下半年的收入将回归到 "前低后高" 的历史常态分布，并呈现出逐季度环比改善的趋势，其中营业收入同比增速将从三季度开始迎来重大 拐点。 # 2024年报数据 迈瑞医疗主要产品覆盖三大 业务 领域， 生命信息与支持、体外诊断以及医学 影像， 叠加"三瑞"智慧生态系统和垂域AI大模型，为医疗机构提供提升整体 诊疗能力的数智化方案。 生命信息与支持 报告期内，公司生命信息与支持业务实现营业收入约 135.57亿元 ，同比 减少11.11%， 其中微创外科业务同比增长超过30%，国际生命信息与支持业务实 现了同比双位数增长。 | | 2024 年 | 2023 年 | 本年比上年增减 | 2022 年 | | --- | --- | --- | --- | --- | | 营业收入(元) | 36,725,749,548.00 | 34,9 ...